SS Innovations International, Inc. (SSII) is a healthcare technology company focused on surgical robotics. The company develops systems that aim to bring robotic-assisted surgery to a broader patient population by offering a lower-cost, modular alternative to established platforms. Investors follow SS Innovations because it operates at the intersection of two long-running trends: the adoption of minimally invasive robotic surgery and rising demand for affordable medical technology in developing economies. I checked a few comparable names in the space using Tickeron’s AI Screener to get a sense of relative positioning.
SS Innovations traces its corporate roots to 2015, when it was incorporated in Florida as AVRA Surgical Microsystems, Inc. The company took its current name and focus in April 2023, when it completed a merger with CardioVentures, Inc., the indirect parent of Sudhir Srivastava Innovations Pvt. Ltd., an India-based developer of surgical robotic technologies. The company's common stock began trading on the Nasdaq Capital Market in April 2025.
The company was founded by Dr. Sudhir Srivastava, a cardiac surgeon widely regarded as a pioneer in robotic heart surgery. His clinical background shapes the company's emphasis on cardiac procedures as well as its broader goal of expanding access to robotic surgery. SS Innovations is headquartered in Gurugram, India, and also maintains a presence in the United States.
SS Innovations operates a classic "razor-and-razorblade" business model. It sells its robotic surgical system, the SSi Mantra, and then generates recurring revenue from the instruments, accessories, and services that hospitals need to keep using it. The SSi Mudra suite includes stapling, energy, and core surgical instrumentation, with more than 40 instrument types supporting multiple specialties, including cardiac surgery.
The SSi Mantra is a modular, multi-arm system featuring an open-faced surgeon console, 3D 4K visualization, and configurable robotic arm carts. The company has also expanded into complementary digital products, including mixed-reality and AI-enabled tools for training, simulation, and visualization, as well as telesurgery capabilities.
Revenue is generated primarily through direct sales and distributor networks, supported by installation, maintenance, technical support, and monitoring services. This model positions SS Innovations not just as a hardware vendor but as an ongoing technology partner to hospitals.
SS Innovations competes in the global surgical robotics market, which has historically been dominated by established players such as Intuitive Surgical (ISRG), maker of the da Vinci system. SS Innovations differentiates itself on cost and accessibility, targeting hospitals and regions where the high acquisition and operating costs of traditional robotic systems have limited adoption. From what I see, the affordability angle is a key differentiator worth tracking.
India is the company's foundational market, where it has built an installed base across private and government hospitals. From that base, it has expanded into countries in Asia, the Middle East, and South America, with stated ambitions for entry into Europe and the United States. The company has also achieved a notable regulatory milestone by becoming, according to its disclosures, the first company in India to receive approval from the Central Drugs Standard Control Organization (CDSCO) for the use of a robotic surgical system in telesurgery and tele-proctoring procedures.
SS Innovations attracts attention as a challenger in a high-growth medical device category. Robotic surgery remains underpenetrated globally, and the company's affordability-focused approach targets a large addressable market that incumbent platforms have often found economically difficult to serve. Its leadership's clinical credentials in cardiac surgery, a specialized and technically demanding field, are a key part of the company's positioning.
The company's financial profile has shown rapid revenue growth as it commercializes the SSi Mantra platform, while its pursuit of U.S. FDA clearance and the EU CE Mark represents a potential catalyst for expansion into the world's largest healthcare markets. The combination of an installed-base strategy, recurring instrument revenue, and a growing pipeline of digital and telesurgery products underpins investor interest in the company's long-term growth story. I’m watching this closely as the regulatory path unfolds.
Investing in SS Innovations carries meaningful risks typical of early-stage medical device companies. The company has historically operated at a net loss and faces ongoing cash-flow considerations as it invests in research, manufacturing, and global expansion. Regulatory approvals in major markets such as the United States and Europe are not guaranteed and can be delayed.
The surgical robotics market is highly competitive, with well-capitalized incumbents and new entrants alike. SS Innovations also faces execution risk as it scales manufacturing and sales across multiple geographies, as well as currency, macroeconomic, and operational risks associated with its concentration in emerging markets. Customer concentration and the pace of hospital adoption of robotic systems are additional factors investors should weigh carefully.
SS Innovations International is an emerging player in surgical robotics with a clear mission: to make robotic-assisted surgery more affordable and accessible worldwide. Its SSi Mantra platform, affordable positioning, cardiac surgery expertise, and global expansion ambitions distinguish it within a competitive medical device industry. As the company pursues larger regulated markets and scales its installed base, SSII remains a notable name for investors interested in the long-term growth of robotic surgery.
In my research, I often turn to Tickeron's AI Screener to quickly compare medical device companies against broader sector trends. It helps surface ideas based on technical indicators, fundamentals, and customizable filters, which can be useful when evaluating names like SSII alongside peers. The platform supports efficient screening across thousands of stocks and ETFs, making it a practical starting point for building or refining a watchlist focused on healthcare technology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 126 of 136 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SSII turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The Aroon Indicator for SSII entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices